49615-96-5

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(3-AMINO-1-BENZOFURAN-2-YL)ETHANONE is used as a building block in the synthesis of pharmaceuticals for its unique structure and reactivity, which contribute to the development of new drugs and therapeutics.
Used in Medicinal Chemistry:
1-(3-AMINO-1-BENZOFURAN-2-YL)ETHANONE is used as a key component in medicinal chemistry to create bioactive molecules, thanks to its versatile chemical properties and potential for various applications in drug development.
Used in Anticancer Research:
In the field of oncology, 1-(3-AMINO-1-BENZOFURAN-2-YL)ETHANONE is used as a compound with potential anticancer properties, being studied for its ability to target and combat cancer cells.
Used in Antimicrobial Applications:
1-(3-AMINO-1-BENZOFURAN-2-YL)ETHANONE is also used as a compound with potential antimicrobial properties, showing promise in the development of new treatments for bacterial and other microbial infections.

InChI:InChI=1/C10H9NO2/c1-6(12)10-9(11)7-4-2-3-5-8(7)13-10/h2-5H,11H2,1H3

Upstream product

• 49615-91-0 2-(2-oxopropoxy)benzonitrile 
• 611-20-1 salicylonitrile 
• 598-31-2 1-bromoacetone 
• 78-95-5 chloroacetone 

Downstream Products

• 94511-08-7 2-acetyl-3-p-toluenesulfonylamidobenzofuran 
• 94511-07-6 2-acetyl-3-N,N-bis(p-toluenesulfonyl)aminobenzofuran 
• 78993-50-7 2-Acetyl-3-phenylacetamidobenzofuran 
• 315701-07-6 2-bromo-3-phenyl-1-(3-acetamido-2-benzofuryl)propen-1-one 
• 315701-04-3 2,3-dibromo-3-phenyl-1-(3-acetamido-2-benzofuryl)propan-1-one 
• 315701-05-4 N-{2-[2,3-dibromo-3-(4-methoxy-phenyl)-propionyl]-benzofuran-3-yl}-acetamide 
• 315701-08-7 N-{2-[2-bromo-3-(4-methoxy-phenyl)-acryloyl]-benzofuran-3-yl}-acetamide 
• 315701-06-5 N-{2-[2,3-dibromo-3-(4-dimethylamino-phenyl)-propionyl]-benzofuran-3-yl}-acetamide 
• 315701-09-8 N-{2-[2-bromo-3-(4-dimethylamino-phenyl)-acryloyl]-benzofuran-3-yl}-acetamide 

Relevant academic research and scientific papers

Synthesis and biological evaluation of benzofuran-based 3,4,5-trimethoxybenzamide derivatives as novel tubulin polymerization inhibitors

A new series of derivatives characterized by the presence of the 3,4,5-trimethoxylbenzamide substituted benzofurans were synthesized and evaluated for antiproliferative activity against four cancer cell lines and one normal human cell line. Among them, de

Xanthine derivatives, their preparation and use

The present invention relates to a xanthine derivative, a pharmaceutically acceptable salt thereof, a solvate of the derivative, a solvate of the pharmaceutically acceptable salt, a chemically protected form or prodrug thereof and a preparation method and a use thereof; and also relates to an intermediate compound used for preparing the xanthine derivative and a preparation method of the intermediate compound. The xanthine derivative and a pharmaceutical composition thereof effectively inhibit the activity of DPP-IV, and can be used for preparing a drug for diseases associated with dipeptidyl peptidase (DPP-IV).

HCV PROTEASE INHIBITORS

The present invention discloses a compound of general formula (I); A is O, S, CH, NH or NR', when O links with Z3, Z1 is N or CRZ1, Z2 is CRZ2, when Z1 links with O, Z2 is CH, Z3 is C-Ar; Ra, Rb, Rc and Rd independently is H, OH, halogen or -Y1-Rm; A1 is NH or CH2; R1' is alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl; A2 is N, O or linking bond; R1 is hydrogen, or, R1 linking covalently with R3 forms C5-C9 saturated or unsaturated hydrocarbon chain substituted by O or N; R3 is alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted by cycloalky etc; R4 is alkoxy-CO, alkyl-NHCO, (alkyl)2NCO, or formyl substituted by aryl, cycloalkyl, heterocycloalkyl.

HCV Protease Inhibitors

A compound of general formula (I); A is O, S, CH, NH or NR′, when O links with Z3, Z1 is N or CRZ1, Z2 is CRZ2, when Z1 links with O, Z2 is CH, Z3 is C—Ar; Ra, Rb, Rc and Rd independently is H, OH, halogen or —Y1—Rm; A1 is NH or CH2; R1′ is alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl; A2 is N, O or linking bond; R1 is hydrogen, or, R1 linking covalently with R3 forms C5-C9 saturated or unsaturated hydrocarbon chain substituted by O or N; R3 is alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted by cycloalkyl etc; R4 is alkoxy-CO, alkyl-NHCO, (alkyl)2NCO, or formyl substituted by aryl, cycloalkyl, heterocycloalkyl.

HCV PROTEASE INHIBITORS

This invention relates to macrocyclic compounds of formula (I) shown in the specification. These compounds can be used to treat hepatitis C virus infection.

HCV PROTEASE INHIBITORS

This invention relates to macrocyclic compounds shown in the specification. These compounds can be used to treat hepatitis C virus infection.

4-SUBSTITUTED-1,5-DIHYDRO-PYRIDO[3,2-B]INDOL-2-ONES

4-substituted 1,5-dihydro-pyrido[3,2-b]indol-2-ones of formula (I): the N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein n is 1, 2 or 3; R1 is hydrogen, cyano, halo, substituted carbonyl, methanimidamidyl, N-hydroxymethanimidamidyl, mono- or di(C1-4alkyl)methanimidamidyl, Het1 or Het2; X is NR 2, O, S, SO, SO2; R2 is hydrogen, C 1-10alkyl, C2-10alkenyl, C 3-7cycloalkyl, which are optionally substituted; R2 is aryl substituted with -COOR4 ; or R2 is: (b-1); (b-2); -CpH2p-CH(OR14 )-CqH 2q-R15(b-3); -CH2-CH2-(O-CH2-CH2)m-OR14 (b-4); -CH2-CH2-(O-CH2-CH2)m-NR5aR5b(b-5); -a1=a2-a3=a4- is -CH=CH-CH=CH-; -N=CH-CH=CH-; -CH=N-CH=CH-; -CH=CH-N=CH-; -CH=CH-CH=N-; wherein hydrogen atoms in (c-1) - (c-5) may be replaced by certain radicals; R3 is obtionally substituted phenyl or a monocyclic or bicyclic aromatic heterocyclic ring system that can be substituted; R21 is halo, hydroxy, amino, carboxyl, C1-6alkyl, C3-7cycloalkyl, arylC1-6alkyl, formyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonylo xy, -C(=O)-NR13R14; C1-6alkyloxy, arylC1-6alkyloxy, polyhaloC1-6alkyloxy, amino, mono or di(C1-6alkyl)amino, formylamino, C1-6alkylcarbonylamino, C1-6alkylsulfo nylamino, mercapto, C1-6alkylthio, arylthio, aryloxy, arylC1-6alkylthio, C1-6alkylsulfynyl, C1-6alkylsulfo nyl, aryl, arylamino, Het1, Het2.

Syntheses of 3-acetoacetylaminobenzo[b]furan derivatives having cysteinyl leukotriene 2 receptor antagonistic activity

Novel 3-acetoacetylaminobenzo[b]furan derivatives having a modified triene system at the 3-position were synthesized starting with 3-aminobenzo[b]furans. The enol isomers, 3-[(3-hydroxybul-2-enonyl)amino]benzo[b]furans (1), of the 3-acetoacetylaminobenzo[b]furans were obtained as stable isomers owing to formation of a hydrogen bonding between the enol hydroxyl group and the amidocarbonyl group. The planarity of the C-2 substituent through the C-3 side chain suggested the existence of a modified conjugational triene system in the enol compound. Cysteinyl leukotriene 1 and 2 receptor antagonistic activities for these compounds were evaluated. 2-(4-Cyanobenzoyl or ethoxycarbonyl)-3-[(2-cyano-3-hydroxybut-2-enonyl)amino]benzo[e]furans (15g, 15o, 15u) were moderately active.

Synthetic Studies in Benzofurans : Part XI - Synthesis of Some Benzofuropyridine Derivatives

Synthesis of 2-acyl-3-aminobenzofurans from salicylonitrile and α-haloketones and their conversion into new tricyclic heterocycle benzofuropyridine derivatives through Friedlanders method are described.Some other routes for the synthesis of various